Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rang in Aktien
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aktienkurs
$4.87
Marktkapitalisierung
$4.36B
Veränderung (1 Tag)
-5.47%
Veränderung (1 Jahr)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategorie
Healthcare
Kursverlauf für Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Höchster Schlusskurs: $5.19 am 2026-10-01
Niedrigster Schlusskurs: $4.81 am 2020-07-01
Niedrigster Schlusskurs: $4.81 am 2020-07-01
Kursverlauf der Aktie von Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd von 2020 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 6.67% |
| 2025 | 188.76% |
| 2024 | -5.91% |
| 2023 | 62.34% |
| 2022 | -30.84% |
| 2021 | -25.95% |
| 2020 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $534.84 | 25.42% |
US
|
|
| $189.00 | 603.91% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $888.12 | 9.08% |
NL
|
